After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.  | After a long, cash-strapped journey, ...

Risankizumab (SKYRIZI®) Met Primary and Key Secondary Endpoints in 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients Jun. 15, 2023 8:45 AM ET AbbVie Inc. (ABBV) ...

PARIS - Abivax SA (Euronext Paris:FR0012333284 - ABVX / Nasdaq: ABVX), a clinical-stage biotechnology company with a market capitalization of $669 million, announced Tuesday that its oral ulcerative ...

The ABTECT program is one of the largest Phase 3 ulcerative colitis trials ever conducted. Abivax to host a conference call and webcast today at 4:30 p.m. EDT (10:30 p.m. CEST) to discuss the results.

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 ...

Abivax SA (NASDAQ:ABVX) shares surged in post-market trading Tuesday after the French biotech firm announced successful Phase 3 trial results for its ulcerative colitis treatment, obefazimod. The oral ...

Shares of Abivax (NASDAQ:ABVX) surged more than 400% in Paris trading on Wednesday after the French biotech company announced that its experimental drug obefazimod met key goals in two pivotal Phase 3 ...

Johnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis May 05, 2025 — 09:33 am EDT Written by RTTNews.com for RTTNews -> ...

Shares of Abivax (NASDAQ:ABVX) rose over 400% in Paris on Wednesday after the French biotech announced that its lead asset, ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

Potential Positives Primary endpoints met in both ulcerative colitis (UC) and Crohn’s disease (CD) indicate a successful Phase 2b study, which is a significant milestone for the company.

50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials ...